EUVIMEDEUVIMED entdecken
Fallbericht

Rifampin-induced bullous pemphigoid in tuberculosis treatment: A strategic rechallenge approach

Vaishnavi V Gaonkar, Vinay V Shanbhag, Mandati Santhosh Reddy, Pratiksha Kini, Bhavana Doshi

American Journal of Health-System Pharmacy · 2026

DOI: 10.1093/ajhp/zxaf218 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Health-System Pharmacy, 2026. Verfasst von Vaishnavi V Gaonkar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, KLE College of Pharmacy, KAHER, Belagavi, Karnataka, India. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Rifampin, Antibiotics, Antitubercular, Tuberculosis. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The purpose of this case report is to highlight an unusual presentation of rifampin-induced bullous pemphigoid in a 37-year-old female undergoing tuberculosis treatment. The report aims to explore the challenges of managing drug-induced bullous pemphigoid while maintaining effective treatment for tuberculosis, emphasizing the necessity of a strategic approach to drug management and disease control. Summary A 37-year-old female with tuberculosis developed an atypical form of bullous pemphigoid during rifampin therapy. The patient presented with painful, pruritic vesicular lesions that directly manifested as bullous lesions without the typical prodromal phase and without mucosal involvement. Histopathological examination confirmed the diagnosis with subepidermal blisters and eosinophilic infiltration. Management of this case involved carefully balancing tuberculosis treatment with bullous pemphigoid control, which required a modified rechallenge protocol, dose titration of rifampin, and a combination of systemic corticosteroids, immunomodulators, and supportive care.

Conclusion

This case underscores the complexity of managing drug-induced bullous pemphigoid in patients undergoing treatment for tuberculosis. The successful outcome was achieved through a cautious approach, including a rechallenge protocol and careful drug dose adjustments. The case offers valuable insights for clinicians managing similar complex presentations of drug-induced bullous pemphigoid, demonstrating that, with a tailored treatment strategy, both conditions can be effectively controlled.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousRifampinAntibiotics, AntitubercularTuberculosisAntitubercular AgentsHumansFemaleAdult

Stichwörter der Autor:innen

antitubercular agentsblistersbullous pemphigoidcutaneous administrationsrechallengerifampin

Substanzen

RifampinAntibiotics, AntitubercularAntitubercular Agents

Autor:innen und Institutionen

  • Department of Pharmacy Practice, KLE College of Pharmacy, KAHER, Belagavi, Karnataka, India.
  • HOD, Department of Dermatology, J N Medical College, KAHER, Belagavi, Karnataka, India.

Zitieren

APA

Gaonkar, V. V., Shanbhag, V. V., Reddy, M. S., Kini, P., & Doshi, B. (2026). Rifampin-induced bullous pemphigoid in tuberculosis treatment: A strategic rechallenge approach. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxaf218

Vancouver

Gaonkar VV, Shanbhag VV, Reddy MS, Kini P, Doshi B. Rifampin-induced bullous pemphigoid in tuberculosis treatment: A strategic rechallenge approach. American Journal of Health-System Pharmacy. 2026. doi:10.1093/ajhp/zxaf218

BibTeX
@article{Gaonkar2026,
  author = {Gaonkar, Vaishnavi V and Shanbhag, Vinay V and Reddy, Mandati Santhosh and Kini, Pratiksha and Doshi, Bhavana},
  title = {Rifampin-induced bullous pemphigoid in tuberculosis treatment: A strategic rechallenge approach},
  journal = {American Journal of Health-System Pharmacy},
  year = {2026},
  doi = {10.1093/ajhp/zxaf218}
}
Kostenlos starten →